PeptiDream Inc., a public Kanagawa-based biopharmaceutical company announced that it has entered into a strategic partnership and license option agreement with Lyon, FRANCE-based Amolyt Pharma, whereby both companies will work together to test and further optimize PeptiDream’s Growth Hormone Receptor Antagonist“GHRA” peptide candidates, with the goal of selecting a clinical candidate for development in acromegaly, a rare endocrine disorder with serious medical complications, to which Amolyt has an option to license the candidates for future clinical development.

Under the terms of the agreement, PeptiDream will be eligible for certain payments associated with the licensing, development, and commercial success of any GHRA product(s), as well as be eligible for certain royalties on future net sales.

“We are pleased to partner with PeptiDream, a leading Japanese biopharmaceutical company with an impressive technology platform for the design of new therapeutic peptides, and whose strategic partners include world class pharmaceutical companies. The potential expansion of our pipeline into acromegaly, where significant unmet needs persist, represents a perfect strategic fit for Amolyt. Given our extensive experience in developing therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases, including our lead clinical candidate, AZP-3601, for hypoparathyroidism, we believe we have the expertise to successfully bring a promising therapy to acromegaly patients in need,” said Thierry Abribat PhD, CEO of Amoylt Pharma.

“We believe Amolyt Pharma is the ideal partner to lead the development of our GHRA peptide candidates and potentially bring an improved treatment paradigm to patients suffering from acromegaly. We are impressed by their therapeutic peptide development capabilities and we are confident in entrusting them with advancing this potentially important asset. We look forward to a mutually beneficial partnership.” said Patrick C. Reid PhD, President & CEO of PeptiDream.